AACR 2023: Single-cell study uncovers distinct immunosuppressive tumour microenvironment in brain metastases from kidney cancer
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest…
Browsing: AACR
AACR 2023: Researchers discover pathway critical for lymphoma development
MYC proteins are important regulators of cancer cell growth, proliferation and metabolism through their ability…
AACR 2023: Study finds thyroid drug ‘normalises’ tumour cells in paediatric brain cancer
Medulloblastoma is the most common malignant brain tumour in children, and few good treatment options…
AACR 2023: Benefit of chemotherapy for patients with early-stage breast cancer varies by tumour anatomy
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center reports…
AACR 2023: Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete…
AACR 2023: Researchers report results in rare gynaecologic cancers from DART immunotherapy trial
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus…
AACR 2023: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that…
AACR 2023: Novel allogeneic CAR T cell therapy delivers promising early results in metastatic clear cell renal cell carcinoma
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and…
AACR 2023: Scientists create powerful, most-accurate tools to research deadliest blood cancer, study says
Tisch Cancer Center scientists developed unique models of the deadliest blood cancer, acute myeloid leukaemia…
AACR 2023: Treatment with immunotherapy alone produces ‘exceptional’ response rates in some melanoma patients
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic…